Vor Biopharma (NASDAQ:VOR - Get Free Report) was upgraded by analysts at Zacks Research to a "strong sell" rating in a report issued on Tuesday, August 12th,Zacks.com reports.
VOR has been the topic of a number of other research reports. Wall Street Zen downgraded Vor Biopharma to a "strong sell" rating in a report on Saturday, June 28th. HC Wainwright upgraded Vor Biopharma from a "hold" rating to a "strong-buy" rating in a report on Monday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Vor Biopharma presently has a consensus rating of "Moderate Buy".
Read Our Latest Report on VOR
Vor Biopharma Trading Up 7.3%
Shares of VOR stock traded up $0.15 on Tuesday, reaching $2.20. 6,022,889 shares of the stock were exchanged, compared to its average volume of 7,952,958. The company has a market cap of $278.70 million, a P/E ratio of -0.16 and a beta of 2.06. Vor Biopharma has a twelve month low of $0.13 and a twelve month high of $3.29.
Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($2.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($1.61).
Vor Biopharma Company Profile
(
Get Free Report)
Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
See Also
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access